Lilly's gastric cancer drug meets late-stage goal

Mon Oct 15, 2012 8:19am EDT

Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.

The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.

The study, named REGARD, also improved survival without the cancer worsening.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.